GemPharmatech (SH:688046)2025-02-27 08:40Financial Performance - Total revenue for 2024 reached RMB 686.80 million, an increase of 10.38% compared to the previous year[3] - Net profit attributable to shareholders decreased by 27.14% to RMB 115.79 million[5] - Basic earnings per share decreased by 28.21% to RMB 0.28[3] Assets and Equity - Total assets at the end of the reporting period were RMB 2,576.24 million, a slight decrease of 0.05% from the beginning of the period[5] - The equity attributable to shareholders increased by 0.76% to RMB 2,140.77 million[5] Research and Development - The company maintained a high level of R&D investment, focusing on strategic projects such as "real-world animal models" and "antibody humanization"[6] Sales and Market Expansion - The company expanded its overseas sales team to over 40 members, covering key regions including North America, Asia-Pacific, and Europe[7] - Increased sales expenses due to the recruitment of additional sales personnel impacted profit margins[7] - The company emphasizes the importance of market expansion and infrastructure investment for future growth and profitability[7] Infrastructure and Operational Costs - New facilities in Beijing, Shanghai, and Guangdong have been completed and are now operational, contributing to increased depreciation expenses[7]